Genetically modified fungus stops malaria... A fungus that produces an insecticide can stop the spread of Anopheles mosquito, which causes malaria. more ➔
Abacus Medicine postpones IPO European pharmaceutical parallel trade company Abacus Medicine A/S has postponed its planned Initial Public Offering (IPO), due to "unfavourable market environment". more ➔
Make leukaemia therapy saferA Belgian-British-Australian research team has created a safer version of a therapy that combats the aggressive form of a blood cancer called acute lymphoblastic leukemia (ALL) while avoiding toxici … more ➔
Nanobiotix spins out CuradigmCancer-focussed Nanobiotix SA has spun out Curadigm, which offers a platform to improve the bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation. more ➔
Double win for NovartisIt was a good day for Novartis: A second drug with huge selling potential has been approved for the US market. The FDA gave the go ahead for breast cancer drug Piqray (alpelisib), the first and only … more ➔
Most expensive gene therapy globally appro... The FDA has approved Novartis-subsidiary AveXis Inc’s spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi). The company wants to set the price tag at $2,125m per dos … more ➔
Healthy figures from SpainAt BioEquity 2019, Spanish Bioindustry Association ASEBIO has given a sneak peek into its 2018 Annual Report, that each year describes the news and trends from the Spanish Biotech Sector. more ➔
Chiesi acquires ex-US Raxone marketing rig...Chiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera Pharmaceuticals for CHF50m (€44m) in cash plus sales milestones. more ➔
EU ministers set to exclude CRISPR crops... EU agriculture ministers want to exclude crops created by targeted mutation methods from EU GMO legislation. more ➔
Evotec acquires CDMO Just Biotherapeutics... Evotec SE is set to acquire biologics manufacturing specialist Just Biotherapeutics, Inc in a deal that could amount up to $90m. more ➔
